Alumis Inc.
ALMS
Rang in aandelen
#10084
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aandeelprijs
$6.61
Marktkapitalisatie
$854.92M
Verandering (1 dag)
4.18%
Verandering (1 jaar)
190.97%
Land
US
Handel Alumis Inc. (ALMS)
Categorie
Healthcare
P/B-ratio voor Alumis Inc. (ALMS)
P/B-ratio op October 2026 TTM: 0.49
Volgens de meest recente financiële rapporten en aandelenkoers van Alumis Inc. is de huidige P/B-ratio (TTM) 0.49. Eind 2023 had het bedrijf een P/B-ratio van 0.80.
P/B-ratiohistoriek voor Alumis Inc. van 2021 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 0.49 | -27.66% |
| 2024 | 0.68 | -14.79% |
| 2023 | 0.80 | -36.26% |
| 2022 | 1.25 | -114.32% |
| 2021 | -8.75 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | 1,170.79% |
US
|
|
| 13.2547 | 2,594.59% |
US
|
|
| 4.208 | 755.46% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 1,156.84% |
NL
|
